Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy.
Felzartamab 用於 IgA Nephropathy 之隨機、雙盲、安慰劑對照第二期a臨床試驗的療效與安全性評估
Kidney Int 2025-06-28
Felzartamab 是一種抗 CD38 抗體,在 IgA 腎病變患者的二期臨床試驗中,能明顯降低蛋白尿(最高劑量降幅約 45%),效果可維持到 24 個月,且能減緩腎功能惡化。藥物安全性不錯,副作用多為輕微。雖然結果樂觀,但還需要更多研究確認長期效果。
相關文章PubMedDOI推理
Dysnatremias in pediatric victims of the 2023 Türkiye-Syria earthquake.
2023年土耳其-敘利亞地震兒童受害者的鈉異常(Dysnatremias)
Pediatr Nephrol 2025-06-27
Global, regional, and national burden of renal anemia, 1990 to 2019 and prediction to 2050.
1990年至2019年全球、區域及國家層級的腎性貧血負擔及至2050年的預測
Nephrol Dial Transplant 2025-06-27
Medium chain fatty acids are potent binding competitors to improve protein-bound uremic toxin clearance during hemodialysis.
中鏈脂肪酸為強效結合競爭者,可提升血液透析期間蛋白結合型尿毒素的清除率
Kidney Int 2025-06-27
Cellular senescence and its association with aldose reductase promote cyst growth in autosomal dominant polycystic kidney disease.
細胞衰老及其與 aldose reductase 的關聯促進自體顯性多囊腎病(ADPKD)囊腫生長
Kidney Int 2025-06-27
Clinical Phenotypes and Renal Outcomes in PLA2R-Associated Membranous Nephropathy: A Multi-Center Cohort Study with Unsupervised Cluster Analysis.
PLA2R相關膜性腎病的臨床表現型與腎臟預後:多中心隊列研究及無監督式叢集分析
Nephrol Dial Transplant 2025-06-27
Longitudinal medication adherence in children with nephrotic syndrome and association with disease outcomes.
兒童腎病症候群的縱向用藥依從性及其與疾病結局的關聯
Nephrol Dial Transplant 2025-06-27